Yuyao Biotechnology key facts
- Developer of new drugs designed for tumors, neurodegenerative diseases, autoimmune diseases and other diseases.
- It has raised $90.3M; the latest was Secondary Transaction - Private in Oct 2025.
- Notable investors include Qiming Venture Partners, Shanghai Highpower Industrial, HuaE Finance Management, Hunan Xiangjiang Xincheng Private Equity Fund Management, Ling Cheng Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·Watch Yuyao Biotechnology: the Monday email on marks, rounds and moves
Yuyao Biotechnology funding rounds
No funding rounds for Yuyao Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Yuyao Biotechnology investors
6 investors are on record for Yuyao Biotechnology, including Qiming Venture Partners, Shanghai Highpower Industrial, HuaE Finance Management and Hunan Xiangjiang Xincheng Private Equity Fund Management.
About Yuyao Biotechnology
Developer of new drugs designed for tumors, neurodegenerative diseases, autoimmune diseases and other diseases. The company offers small molecule drug discovery with artificial intelligence and the development of modern new drug technology, thereby treating major clinical unmet diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Employees
- 50
- Website
- yuyaobiotech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Yuyao Biotechnology doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.